Status:
RECRUITING
Effective Dosing of Burosumab in XLH
Lead Sponsor:
University of Nottingham
Collaborating Sponsors:
Nottingham University Hospitals NHS Trust
Birmingham Women's and Children's NHS Foundation Trust
Conditions:
X-linked Hypophosphatemia (XLH)
Eligibility:
All Genders
2-18 years
Brief Summary
X-linked hypophosphataemia (XLH) is a rare, hereditary condition. The genetic defect leads to low blood phosphate levels and vitamin D suppression. Phosphate is required for strong bones and teeth and...
Detailed Description
X-linked hypophosphatemia (XLH) is a rare, lifelong genetic disorder caused by inactivating mutations in the PHEX gene, leading to elevated levels of fibroblast growth factor 23 (FGF23), which induces...
Eligibility Criteria
Inclusion
- A diagnosis of x-linked hypophosphataemia (XLH) including genetic confirmation of a PHEX mutation.
- Has received at least 12 months of continuous Burosumab treatment under paediatric criteria (given Burosumab is not started till a child is 12 months old in England, the minimum age will, therefore, be 2 years old) prior to their 18th birthday.
Exclusion
- Burosumab received under adult criteria (patients who have received both Burosumab under paediatric arrangements and, subsequently, adult arrangements, can have data obtained during paediatric dosing included).
Key Trial Info
Start Date :
September 8 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT07183579
Start Date
September 8 2025
End Date
January 1 2026
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom, NG7 2UH